RecruitingNCT02639702
Switching from twice-daily to once-daily clozapine in schizophrenia
About this title
Read the official source — NCT02639702Medication studyAges 18+Canada
Understand this study
Who could participate?
This study is for people with schizophrenia. Listed age limits: from 18 years. Other eligibility criteria apply.
What will I do during this study?
Participants are randomly assigned either to switch from twice-daily clozapine to once-daily evening or bedtime dosing, or to continue twice-daily dosing. In the switch group, any dose change is staged at baseline and day 7.
- Listed locations
- TorontoSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: October 15, 2016
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 30
- Sponsor
- Centre for Addiction and Mental Health
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- Canada
- Age range
- Over 18 Years
- Official registry ID
- NCT02639702
- Official title
Show the full official title
Switching From Twice-Daily to Once-Daily Clozapine Dosing in Schizophrenia: A Pilot, Double-Blind, Randomized Controlled Trial
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Toronto
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Centre for Addiction and Mental Health, a hospital or academic medical center.
Does this study involve medication?
Yes. The study involves medication, including Clozapine.
Who can participate?
This study is for people with schizophrenia. Listed age limits: from 18 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as recruiting.
